U.S. Bancorp Growth Deemed IMPRESSIVE and 4 Stock Analyses to Notice Now
Ariad Pharmaceuticals Inc. (NASDAQ:ARIA): Since they believe that the potential use of, “113 drug for ALK mutations,” will become clearer over the next 6-12 months, RBC Capital has increased their target on Ariad Pharmaceuticals Inc. The firm maintains an Outperform rating on their stock.
U.S. Bancorp (NYSE:USB): RBC Capital believes that U.S. Bancorp’s fee income growth and credit quality were impressive during the second quarter, and will continue to improve. The firm maintains an Outperform rating on their stock.
Amarin Corporation PLC (NASDAQ:AMRN): After learning that the FDA originally denied the Lovaza sponsors their request to use EPA-DHA as the generic name for Lovaza, Jefferies says there is added confidence in Amarin Corporation PLC’s new chemical entity prospects for AMR101. Jefferies believes in Amarin’s ability to carve out EPA as a distinct, active moiety, and will argue for five years of exclusivity for the drug. The firm keeps a Buy rating on Amarin, with a $26 price target.
Veolia Environnement S.A. (NYSE:VE): Veolia Environment S.A., has named a long Research Tactical Idea at Morgan Stanley.
Stryker Corp. (NYSE:SYK): After Stryker reported weaker than expected second quarter results, RBC Capital still has confidence that the company will generate a double digit earnings per share growth in the future. The firm maintains an Outperform rating.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.